GU Cancers 2019 | Pembrolizumab/Axitinib and Avelumab/Axitinib combo for RCC
In this video, Matthew Milowsky, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, shares insights on the prospects for treating renal cell carcinoma (RCC). Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Dr Milowsky reports the especially promising results of pembrolizumab plus axitinib, and avelumab plus axitinib in RCC patients.
Transcript (edited for clarity)
Today in kidney cancer, it was really a tremendously exciting day with the presentation of the Pembrolizumab Axitinib data demonstrating survival benefit with a hazard ratio of 0.5. And I think that along with Dr. Schwery’s presentation of the Avelumab Axitinib data with the significant progression-free survival benefit, really transformed the landscape for the management of patients with advanced
Today in kidney cancer, it was really a tremendously exciting day with the presentation of the Pembrolizumab Axitinib data demonstrating survival benefit with a hazard ratio of 0.5. And I think that along with Dr. Schwery’s presentation of the Avelumab Axitinib data with the significant progression-free survival benefit, really transformed the landscape for the management of patients with advanced Renal-Cell Carcinoma, regardless of what their IMDC risk score is. And so I think that we now have a therapy that could potentially be more widely applied to our patients with metastatic renal-cell carcinoma, combining an immune checkpoint inhibitor with a VEGF Receptor Tyrosine Kinase Inhibitor.
Read more...
